Nocicpetor ablation in mice model with #OA - pain was reduced. If its done before OA progression, it helps, but after it doesnt! @AM_Malf work highligted at #EULAR2023 @RheumNow https://t.co/zvxHmlCIrD

#EULAR2023 #LB0005 Can we improve trial design of Bcell depletion in #SLE? Feasibility RCT of RTX in organ specific MSK showed: a)feasible to use ultrasound & clinical as endpoints, b)new tool LAMDA is responsive, c)potential worsening before later improvement with RTX @RheumNow https://t.co/kGDZ6EqLtq

#EULAR2023 recommendation update summary from the 2018 in #PsA whats new! - 3 more drugs now available in PsA. – Guselkumab, Upadacitnib, Risankizumab (1 more in the pipeline) - safety now to to considered! - consider the full picture - extraarticular manifestations @rheumnow https://t.co/7GBILtCX4i

meds for PsA at #EULAR2023 recommendations bDMARD after csDMARD (no order proposed) @RheumNow https://t.co/bHMG4A8nmP

I hurt because the weather is COLD! Data from Rhumadata in 14000 pt encounters show higher pt GLOBAL in winter vs summer - NB cold in Quebec #EULAR2023 POS0324 @RheumNow Small differences but maybe a script to go south is the right Rx! https://t.co/tjd6FjEHij

In ERA high BMI is associated with high BMI is assoc with failure to get to Low disease activity. From NORD-STAR RCT. Cdn CATCH cohort in #early #Rheumatoid #arthritis also shows I is associated w less remission and less sustained remission #EULAR2023 @RheumNow POS0324 https://t.co/9EXY8Dyz74

The thing that can influence bDMARD choice in PsA are the extra-MSK manifestations “A little bit of a paradigm shift here” - Laure Gossec 2023 @eular_org recommendations #EULAR2023 @RheumNow https://t.co/gr9IOg1bbj

Which bDMARD first in PsA? 2023 @eular_org recommendation: no preferred order. All are equal in its eyes #EULAR2023 @RheumNow https://t.co/6HNNamAj1J

Predictive model to predict RA status via AI , to know what goes in to model or predictions may change. Ex use of DMARDs https://t.co/fkcEKfZWl8

PsA recommendations update at #EULAR2023 New overarching principles - should take account of safety @rheumnow https://t.co/rrZ0ViFRPs

We would think that targeted therapies would have reduced GC use in RA. Well, this is not really the case. Comaprison of GC use in 1999-2008 vs. 2009-2018 52% of patients remain on GC for>3Mo after initiation & 1/3 still continues after 2 years! @RheumNow #EULAR23 POS0309 https://t.co/dDkUJFlmEm

Here are the PsA drugs that have come to market in recent years (and what a few years it’s been) #EULAR2023 @RheumNow https://t.co/asFsHAD21y